JPRN-UMIN000013747已完成未知
Investigation of SGLT2 inhibitors for normal glucose tolerance - Investigation of SGLT2 inhibitors for normal glucose tolerance
Dianetes and Endocrinolohgy0 个研究点目标入组 5 人开始时间: 2014年5月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 61years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Type 1 DM (including SPIDDM) 2) Allergy for SGLT2 or Ipragliflozin 3) severe liver dysfunction 4) severe renal dysfunction 5) severe cardiac dysfunction 6) less than 20 years or over 61 years 7) pregnancy or breast feeding 8) mental retardation or dementia 9) systematic steroid administered 10) other inappropriate persons judged by investigators
研究者
相似试验
已完成
不适用
Exploratory study for SGLT2 inhibitor -Glucose lowering action, influences of dietary habits/exercise habits on therapeutic effects, and treatment satisfactioJPRN-UMIN000016993Kanagawa Physicians Association150
已完成
不适用
Efficacy and safety in SGLT2 inhibitor for non-diabetes complicated by non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.JPRN-UMIN000031041Kobe university school of medicine, Diabetes and Endocrinoplogy30
尚未招募
2 期
Mechanisms of action of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF)Heart Failure with Reduced Ejection fractionCardiovascular - Other cardiovascular diseasesACTRN12621000187842The Alfred Hospital36
已完成
不适用
The inhibitory effects of the SGLT2 inhibitor for progression of diabetic nephropathy, in the patients with type 2 diabetes in Japan.diabetic nephropathy in type 2 diabetes mellitusJPRN-UMIN000016754Saitama Medical Center, Saitama Medical University50
进行中（未招募）
1 期
The REFORM TrialType 2 diabetes and Heart FailureEUCTR2014-002742-42-GBniversity of Dundee/ NHS Tayside56